Companies like Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Ovid Therapeutics, and Neuren Pharmaceuticals are coming up with novel therapeutic approaches that can entirely change the treatment landscape of Fragile X Syndrome (FXS).
DelveInsight’s “Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Fragile X Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Fragile X Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Fragile X Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Fragile X Syndrome: An Overview
Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3. It leads to a hypermethylated region in the gene promoter, therefore, silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation. Also, FXS is considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome.
At birth, FXS neonates often exhibit no clinical signs of FXS with most parameters (e.g., head circumference, weight, and height) in the normal range. In early childhood FXS, physical and developmental features become more apparent, including developmental delays, psychomotor delays, intellectual disabilities, and a long face with prominent ears and flat feet. The behavioral phenotype of FXS includes significant anxiety, attention deficit hyperactivity disorder (ADHD), and hyperarousal to sensory stimuli.
Currently, there is no treatment for FXS, but some treatments help minimize the symptoms of the condition The treatment regimen of FXS includes the use of stimulants, selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, and alpha agonists.
The market is expected to grow due the factors like the expected entry of emerging therapies with novel targets and pricing. Furthermore, the impending products such as Zygel, Acamprosate, BPN14770, OV101, and Trofinetide are anticipated to expand the market with more penetration in the 7MM markets.
Fragile X Syndrome Market Key Facts
-
The total diagnosed prevalent population of Fragile X Syndrome in the 7MM was estimated to be around 121,000 in 2021. Additionally, there was a diagnosed prevalent population of ~70,000 cases of FXS in the US.
-
Among the gender-specific prevalent cases, in 2021, there were nearly ~41,000 cases of Fragile X Syndrome in males and nearly ~28,000 cases in females, in the US.
-
The highest number of diagnosed prevalent cases of Fragile X Syndrome (FXS) were recorded in the United States.
-
As per the analysis, Japan recorded ~13,000 cases of Fragile X Syndrome in 2021.
-
Among the five European countries, Germany had the highest diagnosed prevalent population of Fragile X Syndrome (FXS), followed by France and the UK. On the other hand, Spain had the lowest diagnosed prevalent population of Fragile X Syndrome (FXS).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Fragile X Syndrome pipeline therapies. It also thoroughly assesses the Fragile X Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Fragile X Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Fragile X Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Fragile X Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Fragile X Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Fragile X Syndrome Epidemiology, Segmented as –
-
Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) [2019–2032]
-
Gender-specific Cases of Fragile X Syndrome (FXS) [2019–2032]
-
Age-specific Cases of Fragile X Syndrome (FXS) [2019–2032]
Fragile X Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Fragile X Syndrome market or expected to be launched during the study period. The analysis covers the Fragile X Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Fragile X Syndrome drugs based on their sale and market share.
The report also covers the Fragile X Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Fragile X Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Fragile X Syndrome Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market
Fragile X Syndrome Therapeutics Analysis
FXS is the known leading cause of inherited intellectual disability and an autism spectrum disorder. Currently, there is no approved treatment for FXS. The treatment relies on the associated symptoms of the disease which are typically managed using pharmacologic interventions, such as stimulants for attention deficit and hyperactivity, selective serotonin reuptake inhibitors (SSRIs) for anxiety, antipsychotic drugs for aggression and mood instability, and melatonin for sleep.
Several major pharma and biotech companies are developing therapies for Fragile X Syndrome. Currently, Zynerba Pharmaceuticals is leading the therapeutics market with its Fragile X Syndrome drug candidates in the most advanced stage of clinical development.
Fragile X Syndrome Companies Actively Working in the Therapeutics Market Include
-
Zynerba Pharmaceuticals
-
Tetra Therapeutics
-
Autifony Therapeutics
-
Prilenia Therapeutics
-
Alcobra Ltd.
-
Seaside Therapeutics, Inc.
-
Marinus Pharmaceuticals
-
Novartis Pharmaceuticals
-
Neuren Pharmaceuticals
-
Hoffmann-La Roche
-
Healx
-
Nova Mentis
-
Lysogene
-
Actinogen
-
Prilenia Therapeutics
-
Confluence Pharmaceuticals
-
Sentinel Oncology
And Many Others
Emerging and Marketed Fragile X Syndrome Therapies Covered in the Report Include:
-
Zatolmilast: Tetra Discovery Partners
-
Zygel: Zynerba Pharmaceuticals
-
Pridopidine: Prilenia Therapeutics
And Many More
The Report Covers In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Fragile X Syndrome Competitive Intelligence Analysis
4. Fragile X Syndrome Market Overview at a Glance
5. Fragile X Syndrome Disease Background and Overview
6. Fragile X Syndrome Patient Journey
7. Fragile X Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Fragile X Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Fragile X Syndrome Unmet Needs
10. Key Endpoints of Fragile X Syndrome Treatment
11. Fragile X Syndrome Marketed Therapies
12. Fragile X Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Fragile X Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Fragile X Syndrome Market Outlook (In US, EU5, and Japan)
16. Fragile X Syndrome Companies Active in the Market
17. Fragile X Syndrome Access and Reimbursement Overview
18. KOL Views on the Fragile X Syndrome Market
19. Fragile X Syndrome Market Drivers
20. Fragile X Syndrome Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Chronic Idiopathic Constipation Market
“Chronic Idiopathic Constipation Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chronic Idiopathic Constipation market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Chronic Idiopathic Constipation market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology